{"id":61748,"date":"2025-08-20T01:05:30","date_gmt":"2025-08-19T23:05:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/"},"modified":"2025-08-20T01:05:30","modified_gmt":"2025-08-19T23:05:30","slug":"tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/","title":{"rendered":"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation"},"content":{"rendered":"
\n

\nTransforms present balance sheet with significant reduction in liabilities<\/i><\/b><\/p>\n

\nLargest shareholder is long-term strategic investor<\/i><\/b><\/p>\n

NEW YORK–(BUSINESS WIRE)–$TNFA<\/a>–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (\u201cTNF\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cThe recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,\u201d said TNF President and Chief Medical Officer, Mitchell Glass, M.D. \u201cWe are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF\u2019s business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.\u201d<\/p>\n

\nThe improvements in the Company\u2019s financial position will be reflected in future financial statements of the Company.<\/p>\n

\nAbout TNF Pharmaceuticals, Inc.<\/b><\/p>\n

\nTNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-\u03b1, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company\u2019s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit tnfpharma.com<\/a>.<\/b><\/p>\n

\nCautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cwill,\u201d \u201cwould\u2019\u2019 and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company\u2019s ability to maintain compliance with the Nasdaq Stock Market\u2019s listing standards; the timing of, and the Company\u2019s ability to, obtain and maintain regulatory approvals for clinical trials of the Company\u2019s pharmaceutical candidates; the timing and results of the Company\u2019s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company\u2019s ability to retain and attract senior management and other key employees; the Company\u2019s ability to quickly and effectively respond to new technological developments; and the Company\u2019s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company\u2019s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
<\/b>tnfpharma.com\/contact<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor NEW YORK–(BUSINESS WIRE)–$TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (\u201cTNF\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61748","6":"format-standard","7":"category-industry"},"yoast_head":"\nTNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor NEW YORK–(BUSINESS WIRE)–$TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (\u201cTNF\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T23:05:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250819482046\/en\/2310071\/22\/TNF_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation\",\"datePublished\":\"2025-08-19T23:05:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/\"},\"wordCount\":688,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250819482046\\\/en\\\/2310071\\\/22\\\/TNF_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/\",\"name\":\"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250819482046\\\/en\\\/2310071\\\/22\\\/TNF_Logo.jpg\",\"datePublished\":\"2025-08-19T23:05:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250819482046\\\/en\\\/2310071\\\/22\\\/TNF_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250819482046\\\/en\\\/2310071\\\/22\\\/TNF_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/","og_locale":"en_US","og_type":"article","og_title":"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Pharma Trend","og_description":"Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor NEW YORK–(BUSINESS WIRE)–$TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (\u201cTNF\u201d or the \u201cCompany\u201d), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-19T23:05:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250819482046\/en\/2310071\/22\/TNF_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation","datePublished":"2025-08-19T23:05:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/"},"wordCount":688,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250819482046\/en\/2310071\/22\/TNF_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/","url":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/","name":"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250819482046\/en\/2310071\/22\/TNF_Logo.jpg","datePublished":"2025-08-19T23:05:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250819482046\/en\/2310071\/22\/TNF_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250819482046\/en\/2310071\/22\/TNF_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tnf-pharmaceuticals-strengthens-financial-position-for-growth-and-value-creation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61748"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61748\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}